Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
CAS NO.189691-06-3
Pharma grade(10-100)GramPharma grade(101-1000)Gram
1. Rich experiences.
Our company is a professional production leading factory in China in pharmaceutical area of many years. Delivery areas of our products:US, UK, Canada, Australia, Brazil, Russia, Portugal, Latvia, Switzerland, Iceland, Ukraine, Germany, France, Netherlands, Belgium, Peru, Sweden, New Zealand, the Czech Republic, Lithuania, Ireland, Tunisia, Mexico, Greece, Puerto Rico, Thailand, Israel and so on,and we have got very good feedback from our customers, we had established a long friendly relations
Payment method: T/T, , Moneygram
2. Discreet package.
The packing suits you best would be choosen to cross customs safely. Or if you have your own ideal way, it could be also take into consideration .
3. Top quality.
High quality guarenteed, once any problem is found, the package would be reshipped for you
4. Security Shipping.
Shipping by express (FedEx,UPS,DHL,EMS), by air.The most professional forwarder would be recommanded for you.
5. Stock
We have stock, so we can delivery quickly at the very day when receive the payment.
6. Warm after-sale service for you 24/7.
Any of your question would be solved for the first as soon as possible.Adhering to the principle of customer first conviction.we will provide the best and the most sincere services as possible as we can.
7. High quality, best price, first-class service, high successful delivery rate.
A discount would be given when you make a large order.
PT141 Sex Enhancer Peptide Hormone Bremelanotide PT-141
Product Name |
PT 141 |
Synonyms |
Bremelanotide, BREMELANOTIDE PT141, Bremelanotide Acetate |
CAS NO |
189691-06-3
|
Molecular Formula |
C50H68N14O10
|
Molecular Weight |
1025.16
|
Molar Mass |
1025.2
|
Peptide purity |
> 98.0%
|
PubChem |
CID 9941379
|
Appearance |
White lyophilized powder |
Certification |
GBP, ISO9001, FDA |
Standard |
Pharma grade
|
Usage |
Bremelanotide, similarly to its analogues α-MSH and melanotan II, acts as a non-selective agonist of all of the melanocortin |
Packing |
Discreet packing ways as your requirement, 100% go through |
Storage |
Store in cool and dry area and keep away from direct sunlight |
PT-141 (Bremelanotide) is a highly potent synthetic peptide analogue of α-MSH that may elicit aphrodisiac effects through stimulation of melanocortin receptors. PT-141 (Bremelanotide) consists of seven amino acids and is a cyclic, shortened lactam variant of alpha-Melanocyte-stimulating hormone (α-MSH), a multifunctional peptide that regulates a broad array of physiological functions. In studies, bremelanotide was shown to induce lordosis in an animal model and was also effective in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder).
Bremelanotide, similarly to its analogues α-MSH and melanotan II, acts as a non-selective agonist of all of the melanocortin receptors except MC2, where it lacks significant affinity. Reported activity of the drug is as follows:
MC1 (Ki = 0.68 nM)
MC2 (Ki > 1000 nM)
MC3 (Ki = 72.07 nM)
MC4 (Ki = 19.25 nM)
MC5 (Ki = 166.8 nM)
Bremelanotide appears to stimulate sexual desire and arousal completely or mostly via activation of the MC4 receptor (the MC3 receptor may also be involved). It modulates inflammation and limits ischemia via activation of the MC1 and MC4 receptors.
According to Palatin Technologies' original 2003 patent for bremelanotide, it possesses approximately 50 times the potency of melanotan II as an inducer of erection in male rats. In addition, it was stated in the patent that the therapeutic window of bremelanotide in animals (specifically, the range of induction of the desired sexual arousal relative to the induction of side effects including nausea, yawning, stretching, and decreased appetite) was >1,000-fold, whereas that of melanotan II was only 3- to 4-fold. They concluded that bremelanotide would be more tolerable than melanotan II.